NCT03365791: PDR001 Plus LAG525 for Patients With Advanced Solid and Hematologic Malignancies |
|
|
| Completed | 2 | 76 | US | PDR001, LAG525 | Novartis Pharmaceuticals | Small Cell Lung Cancer, Gastric Adenocarcinoma, Esophageal Adenocarcinoma, Castration Resistant Prostate Adenocarcinoma, Soft Tissue Sarcoma, Ovarian Adenocarcinoma, Advanced Well-differentiated Neuroendocrine Tumors, Diffuse Large B Cell Lymphoma | 02/19 | 09/20 | | |
